Most Popular Choices
Become a Premium Member Would you like to know how many people have visited this page? Or how reputable the author is? Simply sign up for a Advocate premium membership and you'll automatically see this data on every article. Plus a lot more, too.


(920) 251-3740
SHARE More Sharing

Chuck Bennett, M.D., CDR, USN (Ret)

Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

                 

Volunteer a little time and make a big difference

Become a Fan
Become a Fan.
You'll get emails whenever I post articles on OpEd News

As an anesthesiologist frequently involved in critical and intensive care, I often treat terminal cancer patients for, among other things, side effects of chemotherapy. Some of my treatments include: invasive central venous catheters for transfusions secondary to chemo induced anemia and neutropenia, management of pain and refractory nausea/emesis secondary to chemo. If a medicine can obviate or at least reduce the use of a toxic drug(such as chemo), then it would noticeably affect the pain and suffering I witness and treat.

OpEd News Member for 841 week(s) and 6 day(s)

2 Articles, 0 Quick Links, 0 Comments, 0 Diaries, 0 Polls

Articles Listed By Date
List By Popularity
Search Title   
Date Between and
SHARE More Sharing        Saturday, June 21, 2008
Support the ACCESS Act Prostate cancer advocates support the ACCESS Act and we need your help. Please read and sign petition. We all get sick and we are all affected by cancer. The life you save may be your own or someone you love. Please help us.
(1 comments) SHARE More Sharing        Sunday, February 10, 2008
Tell the truth, the whole truth, and nothing but the truth: What really happened with Provenge?? Open letter to the Energy and Commerce Committee and Subcommittees on Health and Oversight and Investigations written by several physicians urging an investigation into the FDA's handling of Provenge, an immunotherapy treatment for late stage prostate cancer.

Tell A Friend